Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer

被引:110
作者
Kesharwani, Prashant [1 ]
Tekade, Rakesh K. [2 ]
Jain, Narendra K. [1 ]
机构
[1] Dr HS Gout Univ, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India
[2] Univ Hawaii, Coll Pharm, Dept Pharmaceut Sci, Hilo, HI 96720 USA
关键词
Dendrimer; Generations; Cancer; Drug delivery; Toxicity; IMINE) DENDRIMERS; DRUG-DELIVERY; IN-VITRO; ASSAY;
D O I
10.1016/j.biomaterials.2014.03.064
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Dendrimer-mediated delivery of bioactive is a successful and widely explored concept. This paper desribes comparative data pertaining to generation dependent cancer targeting propensity of Poly(propyleneimine) (PPI) dendrimers. This debut report reportsthe drug targeting and antciancer potential of different dendrimer generations. PPI dendrimers of different generations (3.0G, 4.0G and 5.0G) were synthesized and loaded with Melphalan. Results from loading, hemolysis, hematologic, cytotoxicty and flow cytometry assay depicted that as the generation of dendrimer increased from fourth to fifth, the only parameter i.e. toxicty is increased exponentionally. However, others parameters, i.e. loading, sustained release behavior, and targeting efficacy increased negligibly. Kaplan-Meier survival curves clearly depicted comparable therapeutic potential of PPI4M with PPI5M. In vivo investigations in BaIb/c mice again favored 4.0G PPI dendrimer to be preferable nanocarrier for anticancer drug delivery owing to analogous anticancer potential. The outcomes of the investigation evidently projects 4.0G PPI dendrimer over 3.0G and 5.0G dendrimer in respect of its drug delivery benefit as well as superior biocompatibility. Thus, much against the common belief, 4.0G PPI dendrimers may be considered to be optimum in respect of drug delivery precluding the use of much more toxic 5.0G PPI dendrimer, which offers no benefit over 4.0G. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5539 / 5548
页数:10
相关论文
共 24 条
  • [1] Nanomedicines as Cancer Therapeutics: Current Status
    Akhter, Sohail
    Ahmad, Iqbal
    Ahmad, Mohammad Zaki
    Ramazani, Farshad
    Singh, Anjali
    Rahman, Ziyaur
    Ahmad, Farhan Jalees
    Storm, Gert
    Kok, Robbert J.
    [J]. CURRENT CANCER DRUG TARGETS, 2013, 13 (04) : 362 - 378
  • [2] Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur
    Arias, Jose L.
    Lopez-Viota, Margarita
    Gallardo, Visitacion
    Adolfina Ruiz, Maria
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2010, 36 (06) : 744 - 750
  • [3] Low generation PEGylated phosphorus-containing dendrons with phosphonate anchors
    Barriere, Clement
    Latour, Virginie
    Fau, Pierre
    Caminade, Anne-Marie
    Turrin, Cedric-Olivier
    [J]. TETRAHEDRON LETTERS, 2012, 53 (15) : 1908 - 1911
  • [4] Boas U., 2006, P1, DOI 10.1039/9781847552679-00001
  • [5] USE OF AN AQUEOUS SOLUBLE TETRAZOLIUM FORMAZAN ASSAY FOR CELL-GROWTH ASSAYS IN CULTURE
    CORY, AH
    OWEN, TC
    BARLTROP, JA
    CORY, JG
    [J]. CANCER COMMUNICATIONS, 1991, 3 (07): : 207 - 212
  • [6] Dendrimer-drug interactions
    D'Emanuele, A
    Attwood, D
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (15) : 2147 - 2162
  • [7] FUNCTIONAL POLYMERS AND DENDRIMERS - REACTIVITY, MOLECULAR ARCHITECTURE, AND INTERFACIAL ENERGY
    FRECHET, JMJ
    [J]. SCIENCE, 1994, 263 (5154) : 1710 - 1715
  • [8] Kesharwani P, 2014, NANOMED LOND
  • [9] Dendrimer as nanocarrier for drug delivery
    Kesharwani, Prashant
    Jain, Keerti
    Jain, Narendra Kumar
    [J]. PROGRESS IN POLYMER SCIENCE, 2014, 39 (02) : 268 - 307
  • [10] Carbon nanotube exploration in cancer cell lines
    Kesharwani, Prashant
    Ghanghoria, Raksha
    Jain, Narendra K.
    [J]. DRUG DISCOVERY TODAY, 2012, 17 (17-18) : 1023 - 1030